SEC Company Response from MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813) — Jul 16, 2020
MARINUS PHARMACEUTICALS, INC. (MRNS) (CIK 0001267813)
Date: July 16, 2020 · CIK: 0001267813 · Accession: 0001104659-20-084038
AI Filing Summary & Sentiment
File numbers found in text: 333-239780
Letter
Marinus Pharmaceuticals, Inc.
5 Radnor Corporate Center, Suite 500
100 Matsonford Rd
Radnor, PA 19087
July 16, 2020
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attn: Jeffrey Gabor
Re: Marinus Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed July 9, 2020
File No. 333-239780
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Marinus Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and declare the Registration Statement effective as of 4:00 p.m., Eastern Daylight Time, on July 20, 2020, or as soon thereafter as possible.
Please feel free to direct any questions or comments concerning this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.
Very truly yours,
Marinus Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Marinus Pharmaceuticals, Inc.
5 Radnor Corporate Center, Suite 500
100 Matsonford Rd
Radnor, PA 19087
July 16, 2020
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attn: Jeffrey Gabor
Re: Marinus Pharmaceuticals, Inc.
Registration Statement
on Form S-3
Filed July 9, 2020
File No. 333-239780
Request for
Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of
the General Rules and Regulations under the Securities Act of 1933, as amended, Marinus Pharmaceuticals, Inc. hereby requests that
the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3
(the “Registration Statement”), and declare the Registration Statement effective as of 4:00 p.m., Eastern Daylight
Time, on July 20, 2020, or as soon thereafter as possible.
Please feel free to direct
any questions or comments concerning this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.
Very truly yours,
Marinus Pharmaceuticals, Inc.
/s/ Edward F. Smith
By:
Edward F. Smith
Title:
Vice President, Chief Financial Officer, Secretary and Treasurer